Clinical trial · Observational
The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, retrospective and prospective, long-term registry of patients with benign or malignant hematologic diseases, whether or not these patients were or were not treated with disease-specific treatments. Information will be collected on patient demographics, disease characteristics, genomic and molecular data, laboratory data, pathology, radiographic reports, clinical status, quality of life, medications, and dosing information. Where appropriate, these data structures may be based on a combination of Fast Healthcare Interoperability Resources (FHIR) , Consolidated-Clinical Data Architecture (C-CDA) and/or client-specific structure definitions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign and Malignant Hematologic Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Protease Inhibitors | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational/ Interventional
- description
- Hematologic Disease
- interventionNames
- Combination Product: Protease Inhibitors
Primary outcomes (1)
- measure
- Minimal Residual Disease
- timeFrame
- Up to 5 Years
- description
- Cancer cells from the bone marrow) that remain in the patient during treatment, or after treatment when the patient is in remission e.g. 3 months, 6 months, one year, or end of current treatment.
Secondary outcomes (1)
- measure
- Patient reported outcomes (health-related QoL )
- timeFrame
- Up to 5 Years
- description
- Health-related QoL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients (\>18 years of age) must have diagnostically- or investigator-confirmed benign or malignant hematologic disease. * For prospective data collection efforts within the ASH Registry that require informed consent, children (\<18 years of age) with hematologic disease whose parent/legal guardian consents on their behalf may be included. Exclusion Criteria: * Adults that are unable to consent. * Prisoners
References
Publications (0)
Data not yet available